scholarly journals Compassionate Use of a Single Dose of Benralizumab in a Near-Fatal Asthma Exacerbation

2020 ◽  
Vol 31 (3) ◽  
Author(s):  
L Pérez de Llano ◽  
N Blanco Cid ◽  
M Ortiz Piquer ◽  
D Dacal Rivas
Keyword(s):  
Single Dose ◽  
Asthma Exacerbation ◽  
Compassionate Use ◽  
Fatal Asthma ◽  
Near Fatal Asthma

Potentially (near) fatal asthma

2019 ◽  
Vol 40 (6) ◽  
pp. 403-405 ◽  
Author(s):  
Paul A. Greenberger
Keyword(s):  
Severe Asthma ◽  
Health Care Professionals ◽  
Rescue Therapy ◽  
Respiratory Acidosis ◽  
Acute Severe Asthma ◽  
Increased Risk ◽  
High Risk Type ◽  
Fatal Asthma ◽  
Long Acting ◽  
Near Fatal Asthma

Potentially (near) fatal asthma (PFA) defines a subset of patients with asthma who are at increased risk for death from their disease. The diagnosis of PFA should motivate treating physicians, health professionals, and patients to be more aggressive in the monitoring, treatment, and control of this high-risk type of asthma. A diagnosis of PFA is made when any one of the following are present: (1) a history of endotracheal intubation from asthma, (2) acute respiratory acidosis (pH < 7.35) or respiratory failure from acute severe asthma, (3) two or more episodes of acute pneumothorax or pneumomediastinum from asthma, (4) two or more episodes of acute severe asthma, despite the use of long-term oral corticosteroids and other antiasthma medications. There are two predominant phenotypes of near-fatal exacerbations: “subacute” exacerbation and “hyperacute” exacerbation. The best way to “treat” acute severe asthma is 3‐7 days before it occurs (i.e., at the onset of symptoms or change in respiratory function) and to optimize control of asthma by decreasing the number of symptomatic days and the days and/or nights that require rescue therapy and increasing baseline respiratory status in “poor perceivers.” PFA is treated with a multifaceted approach; physicians and health-care professionals should appreciate limitations of pharmacotherapy, including combination inhaled corticosteroid‐long-acting β-agonist products as well as addressing nonadherence, psychiatric, and socioeconomic issues that complicate care.

scholarly journals Part 10.5: Near-Fatal Asthma

Circulation ◽  
2005 ◽  
Vol 112 (24_suppl) ◽  
pp. IV-139-IV-142
Keyword(s):  
Fatal Asthma ◽  
Near Fatal Asthma

Rhabdomyolysis after successful resuscitation of a patient with near-fatal asthma

2007 ◽  
Vol 25 (6) ◽  
pp. 736.e3-736.e4 ◽  
Author(s):  
Yi-Jung Chen ◽  
Shih-Heng Chang ◽  
Ang Yuan ◽  
Chien-Hua Huang ◽  
Chien-Chang Lee
Keyword(s):  
Successful Resuscitation ◽  
Fatal Asthma ◽  
Near Fatal Asthma

Identifying An At-Risk Population of Children With Recurrent Near-Fatal Asthma Exacerbations

2010 ◽  
Vol 47 (4) ◽  
pp. 460-464 ◽  
Author(s):  
Christopher L. Carroll ◽  
Burcin Uygungil ◽  
Aaron R. Zucker ◽  
Craig M. Schramm
Keyword(s):  
At Risk ◽  
Risk Population ◽  
Asthma Exacerbations ◽  
Fatal Asthma ◽  
Near Fatal Asthma

A community-based study of near-fatal asthma

2001 ◽  
Vol 86 (2) ◽  
pp. 190-195 ◽  
Author(s):  
Brad B. Moore ◽  
Robin Wagner ◽  
Kevin B. Weiss
Keyword(s):  
Community Based ◽  
Fatal Asthma ◽  
Near Fatal Asthma

scholarly journals 279 Near-Fatal Asthma Treated with Omalizumab

2012 ◽  
Vol 5 ◽  
pp. S91
Author(s):  
Elvia Angelica Contreras Contreras ◽  
María Elena Ramírez Del Pozo ◽  
Javier Gomez Vera ◽  
Jesus Lopez Tiro
Keyword(s):  
Fatal Asthma ◽  
Near Fatal Asthma
Sign in / Sign up

Export Citation Format

Share Document